Zeki İlker KUNAK, Mehmet TOYGAR, YAVUZ POYRAZOĞLU

Sülfür mustard toksisitesine karşı yeni moleküler stratejiler

Kullanılabilir kimyasal savaş ajanları içinde, hardal gazı olarak ta bilinen sülfür mustard (SM) kimyasal silah olarak yaygın şekilde kullanılmaktadır. Kapasite düşürücü bir ajan olarak SM toksisitesi, öldürücü kabiliyetinden çok daha tehlikelidir. Akut SM ile indüklenmiş hücresel toksisite hakkındaki bilinenlerin aksine, maalesef hardal gazının tek dozuna maruz kalınmasından yıllar sonra nasıl ciddi çoklu organ hasarı oluşturduğu açık değildir. Antioksidan ve antienflamatura ilaçları içeren bir kısım tedavi çeşitlemeleri ve diğerleri güvenilir olmayan sonular vermiştir. A variety of treatment modalities including antioxidants, anti-inflammatory drugs and others have resulted no promising results. Epigenetik aberasyonların mustard zehirlenmesinde etkisi üzerine bir deneme yaptık.

Novel molecular strategies against sulfur mustard toxicit

Among the available chemical warfare agents, sulfur mustard (SM), also known as mustard gas, has been widely used chemical weapon. In our laboratory, we have shown that, acute toxicity of SM is related to reactive oxygen and nitrogen species, DNA damage, poly(ADP-ribose) polymerase activation and energy depletion within the affected cell. In spite of the knowledge about acute SM-induced cellular toxicity, unfortunately, it is not clear how mustard gas causes severe multi-organ damage years after even a single exposure. A variety of treatment modalities including antioxidants, anti-inflammatory drugs and others have resulted no promising results. We, therefore, made an attempt whether epigenetic aberrations may contribute to pathogenesis of mustard poisoning. The term epigenetic describes the study of inheritable alterations in gene expression that occur in the absence of changes in genome sequence. Therefore, epigenetic gene regulation requires molecular mechanisms that encode information in addition to the DNA base sequence and can be propagated through mitosis and meiosis. Our current understanding of epigenetic regulation of gene expression involves basically two classes of molecular mechanisms: histone modifications and DNA methylation. Preliminary evidence obtained from our laboratory reveals that exposure to mustards may not only cause nitro-oxidative stress and DNA (genetic) damage, but epigenetic perturbations as well. Epigenetic therapy is a new and rapidly developing field in pharmacology. Epigenetic drugs alone or in combination with conventional drugs may prove to be a significant advance over the conventional drugs used to treat both acute and delayed SM toxicity. Future studies are urgently needed to clarify the mechanism of delayed SM-induced toxicity and novel treatment modalities.

PDF

___

1. Smith KJ, Skelton H. Chemical warfare agents: their past and continuing threat and evolving therapies. Part II of II. Skinmed. 2003; 2: 297.
2. Kehe K, Szinicz L. Medical aspects of sulphur mustard poisoning. Toxicology. 2005; 214: 198.
3. Laskin JD, Black AT, Jan YH, et al. Oxidants and antioxidants in sulfur mustard-induced injury. Ann N Y Acad Sci. 2010; 1203: 92.
4. Korkmaz A, Topal T, Oter S. Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol. 2007; 23: 303.
5. Korkmaz A, Yaren H, Topal T, Oter S. Molecular targets against mustard toxicity: implication of cell surface receptors, peroxynitrite production, and PARP activation. Arch Toxicol. 2006; 80: 662.
6. Yildirim I, Korkmaz A, Oter S, Ozcan A, Oztas E. Contribution of antioxidants to preventive effect of mesna in cyclophosphamide-induced hemorrhagic cystitis in rats. Cancer Chemother Pharmacol. 2004; 54: 469.
7. Ozcan A, Korkmaz A, Oter S, Coskun O. Contribution of flavonoid antioxidants to the preventive effect of mesna in cyclophosphamide-induced cystitis in rats. Arch Toxicol. 2005; 79: 461.
8. Sadir S, Deveci S, Korkmaz A, Oter S. Alpha-tocopherol, beta-carotene and melatonin administration protects cyclophosphamide-induced oxidative damage to bladder tissue in rats. Cell Biochem Funct. 2007; 25: 521.
9. Korkmaz A, Oter S, Deveci S, et al. Involvement of nitric oxide and hyperbaric oxygen in the pathogenesis of cyclophosphamide induced hemorrhagic cystitis in rats. J Urol. 2003; 170: 2498.
10. Oter S, Korkmaz A, Oztas E, Yildirim I, Topal T, Bilgic H. Inducible nitric oxide synthase inhibition in cyclophosphamide induced hemorrhagic cystitis in rats. Urol Res. 2004; 32: 185.
11. Topal T, Oztas Y, Korkmaz A, et al. Melatonin ameliorates bladder damage induced by cyclophosphamide in rats. J Pineal Res. 2005; 38: 272.
12. Ucar M, Korkmaz A, Reiter RJ, et al. Melatonin alleviates lung damage induced by the chemical warfare agent nitrogen mustard. Toxicol Lett. 2007; 173: 124.
13. Korkmaz A, Oter S, Sadir S, et al. Peroxynitrite may be involved in bladder damage caused by cyclophosphamide in rats. J Urol. 2005; 173: 1793.
14. Yaren H, Mollaoglu H, Kurt B, et al. Lung toxicity of nitrogen mustard may be mediated by nitric oxide and peroxynitrite in rats. Res Vet Sci. 2007; 83: 116.
15. Demicheli V, Quijano C, Alvarez B, Radi R. Inactivation and nitration of human superoxide dismutase SOD by fluxes of nitric oxide and superoxide. Free Radic Biol Med. 2007; 42: 1359.
16. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007; 87: 315.
17. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem. 2001; 276: 29596.
18. Wu J, Akaike T, Hayashida K, Okamoto T, Okuyama A, Maeda H. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn J Cancer Res. 2001; 92: 439.
19. Szabo C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett. 2003; 140-141: 105.
20. Whang YE, Wu X, Suzuki H, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA. 1998; 95: 5246.
21. Juedes MJ, Wogan GN. Peroxynitrite-induced mutation spectra of pSP189 following replication in bacteria and in human cells. Mutat Res. 1996; 349: 51.
22. Masuda M, Nishino H, Ohshima H. Formation of 8-nitroguanosine in cellular RNA as a biomarker of exposure to reactive nitrogen species. Chem Biol Interact. 2002; 139: 187.
23. Tamir S, deRojas-Walker T, Wishnok JS, Tannenbaum SR. DNA damage and genotoxicity by nitric oxide. Methods Enzymol. 1996; 269: 230.
24. Yoshie Y, Ohshima H. Nitric oxide synergistically enhances DNA strand breakage induced by polyhydroxyaromatic compounds, but inhibits that induced by the Fenton reaction. Arch Biochem Biophys. 1997; 342: 13.
25. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998; 351: 28.
26. Yermilov V, Yoshie Y, Rubio J, Ohshima H. Effects of carbon dioxide/bicarbonate on induction of DNA single-strand breaks and formation of 8-nitroguanine, 8-oxoguanine and base-propenal mediated by peroxynitrite. FEBS Lett. 1996; 399: 67.
27. Chien YH, Bau DT, Jan KY. Nitric oxide inhibits DNA-adduct excision in nucleotide excision repair. Free Radic Biol Med. 2004; 36: 1011.
28. Virag L, Szabo E, Gergely P, Szabo C. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol Lett. 2003; 140-141: 113.
29. Kehe K, Raithel K, Kreppel H, Jochum M, Worek F, Thiermann H. Inhibition of polyADP-ribose polymerase PARP influences the mode of sulfur mustard SM-induced cell death in HaCaT cells. Arch Toxicol. 2008; 82: 461.
30. Korkmaz A, Kurt B, Yildirim I, et al. Effects of polyADP-ribose polymerase inhibition in bladder damage caused by cyclophosphamide in rats. Exp Biol Med Maywood. 2008; 233: 338.
31. Somani SM, Babu SR. Toxicodynamics of sulfur mustard. Int J Clin Pharmacol Ther Toxicol. 1989; 27: 419.
32. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003; 102: 43.
33. Balali-Mood M, Hefazi M. Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic Clin Pharmacol Toxicol. 2006; 99: 273.
34. Balali-Mood M, Hefazi M, Mahmoudi M, et al. Long-term complications of sulphur mustard poisoning in severely intoxicated Iranian veterans. Fundam Clin Pharmacol. 2005; 19: 713.
35. Shohrati M, Peyman M, Peyman A, Davoudi M, Ghanei M. Cutaneous and ocular late complications of sulfur mustard in Iranian veterans. Cutan Ocul Toxicol. 2007; 26: 73.
36. Hefazi M, Attaran D, Mahmoudi M, Balali-Mood M. Late respiratory complications of mustard gas poisoning in Iranian veterans. Inhal Toxicol. 2005; 17: 587.
37. Mahmoudi M, Hefazi M, Rastin M, Balali-Mood M. Long-term hematological and immunological complications of sulfur mustard poisoning in Iranian veterans. Int Immunopharmacol. 2005; 5: 1479.
38. Nohmi T, Kim SR, Yamada M. Modulation of oxidative mutagenesis and carcinogenesis by polymorphic forms of human DNA repair enzymes. Mutat Res. 2005; 591: 60.
39. Szabo E, Virag L, Bakondi E, et al. Peroxynitrite production, DNA breakage, and polyADP-ribose polymerase activation in a mouse model of oxazolone-induced contact hypersensitivity. J Invest Dermatol. 2001; 117: 74.
40. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst. 2005; 97: 1498.
41. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002; 16: 6.
42. Bronner C, Chataigneau T, Schini-Kerth VB, Landry Y. The "Epigenetic Code Replication Machinery", ECREM: a promising drugable target of the epigenetic cell memory. Curr Med Chem. 2007; 14: 2629.
43. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet. 2000; 9: 2395.
44. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007; 26: 5310.
45. McLachlan JA. Environmental signaling: what embryos and evolution teach us about endocrine disrupting chemicals. Endocr Rev. 2001; 22: 319.
46. Gallou-Kabani C, Junien C. Nutritional epigenomics of metabolic syndrome: new perspective against the epidemic. Diabetes. 2005; 54: 1899.
47. McLachlan JA, Burow M, Chiang TC, Li SF. Gene imprinting in developmental toxicology: a possible interface between physiology and pathology. Toxicol Lett. 2001; 120: 161.
48. Bombail V, Moggs JG, Orphanides G. Perturbation of epigenetic status by toxicants. Toxicol Lett. 2004; 149: 51.
49. Jiang YH, Bressler J, Beaudet AL. Epigenetics and human disease. Annu Rev Genomics Hum Genet. 2004; 5: 479.
50. Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C. Cancer genetics of epigenetic genes. Hum Mol Genet. 2007; 16(1): R28.
51. Ducasse M, Brown MA. Epigenetic aberrations and cancer. Mol Cancer. 2006; 5: 60.
52. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene. 2001; 20: 3139.
53. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007; 16(1): R50.
54 Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 2004; 22: 4632.
55. Garinis GA, Patrinos GP, Spanakis NE, Menounos PG. DNA hypermethylation: when tumour suppressor genes go silent. Hum Genet. 2002; 111: 115.
56. Brueckner B, Kuck D, Lyko F. DNA methyltransferase inhibitors for cancer therapy. Cancer J. 2007; 13: 17.
57. Peedicayil J. Epigenetic therapy--a new development in pharmacology. Indian J Med Res. 2006;1 23: 17.
58. Balali-Mood M, Hefazi M. The pharmacology, toxicology, and medical treatment of sulphur mustard poisoning. Fundam Clin Pharmacol. 2005; 19: 297.
59. Khateri S, Ghanei M, Keshavarz S, Soroush M, Haines D. Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J Occup Environ Med. 2003; 45: 1136.
60. Korkmaz A, Kunak ZI, Paredes SD, Yaren H, Tan DX, Reiter RJ. The use of melatonin to combat mustard toxicity. REVIEW. Neuro Endocrinol Lett. 2008; 29: 614.
61. Korkmaz A, Yaren H, Kunak ZI, et al. Epigenetic perturbations in the pathogenesis of mustard toxicity; hypothesis and preliminary results. Interdiscip Toxicol. 2008; 1: 236.